ArticlePharmacoEconomics - open2021

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial.

Yoav Golan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.